Aniracetam — Nootropic Benefits, What People Report, and Research Context
Aniracetam is a fat-soluble nootropic in the racetam family, first developed in the 1970s. Based on self-reported experience logs on Narrated, it is most commonly logged for cognitive performance and anxiety reduction. Aniracetam is not FDA-approved in the United States and is classified as a nootropic compound.
What is aniracetam?
Aniracetam (1-p-anisoyl-2-pyrrolidinone) is a synthetic nootropic compound belonging to the racetam class. It was developed by Hoffmann-La Roche in the 1970s and is structurally related to piracetam. It is generally described in pharmacological literature as more potent by weight than piracetam. It is fat-soluble, meaning it is typically taken with food containing fats for absorption.
According to published pharmacological research, aniracetam modulates AMPA receptors (a type of glutamate receptor), which is hypothesized to underlie its cognitive effects. It is also described in the literature as influencing cholinergic, dopaminergic, and serotonergic systems.
What is the regulatory status of aniracetam?
As of March 2026:
- United States: Not FDA-approved. Available as a dietary supplement / research compound. Not scheduled as a controlled substance.
- United Kingdom: Not a licensed medicine. Legal to possess for personal use.
- European Union: Prescription medication in some EU countries (notably Italy and France, where it is marketed as Ampamet).
- Japan: Approved as a prescription drug for cognitive disorders.
The regulatory gap is notable — aniracetam is a prescription medication in some countries but an unregulated supplement in others.
What nootropic benefits do people report?
Based on self-reported experience logs on Narrated, people commonly report the following when using aniracetam:
| Most common reported benefit | Improved verbal fluency |
|---|---|
| Second most common | Reduced anxiety in social situations |
| Third most common | Enhanced focus and concentration |
| Fourth | Improved creative thinking |
| Commonly reported onset | 30-60 minutes after dosing |
Many logs describe aniracetam as providing a "smooth" cognitive effect rather than stimulation. The anxiolytic (anxiety-reducing) effect is frequently reported alongside cognitive benefits, which is somewhat unique among racetam nootropics.
What are the reported side effects of aniracetam?
From self-reported logs on Narrated:
| None reported | Most common response |
|---|---|
| Headache (without choline) | Moderately reported |
| Mild digestive discomfort | Occasionally reported |
| Irritability (at high doses) | Rarely reported |
The most notable pattern in self-reported logs: headaches are frequently mentioned alongside not co-administering a choline source. Some experience logs on Narrated mention co-administration with choline sources such as alpha-GPC or citicoline.
What does the research say about aniracetam?
Aniracetam has been studied in both animal models and human clinical trials:
- Animal studies show enhancement of long-term potentiation and memory formation
- Human trials in Japan and Europe have focused on cognitive decline in elderly populations
- AMPA receptor modulation is well-documented in pharmacological research
- Research depth rating on Narrated: Moderate
- Long-term safety data in healthy adults is limited
How does aniracetam compare to other racetams?
People who log racetams on Narrated often try multiple variants. Common comparisons in self-reported data:
- vs. Piracetam: Aniracetam is reported as more potent per dose, with stronger anxiolytic effects
- vs. Phenylpiracetam: Phenylpiracetam is reported as more stimulating, aniracetam as more subtle
- vs. Oxiracetam: Oxiracetam is reported as better for pure focus, aniracetam for verbal fluency
These are self-reported patterns, not clinical comparisons.
Is this medical advice?
No. Narrated aggregates self-reported community data. We do not recommend, rank, or advise the use of any compound. Always consult a healthcare professional.